| 标题 |
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Clinical Lymphoma, Myeloma & Leukemia 作者:Meletios Α. Dimopoulos; Pieter Sonneveld; Paula Rodríguez‐Otero; Hang Quach; P. Joy Ho; et al 出版日期:2024-08-26 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)